Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.
Luis Puig, Philipp Sewerin, Christopher Schuster, Khai Jing Ng, Manny Papadimitropoulos, Sneha Gadagamma, Mercedes Nuñez, Anastasia Lampropoulou
{"title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.","authors":"Luis Puig, Philipp Sewerin, Christopher Schuster, Khai Jing Ng, Manny Papadimitropoulos, Sneha Gadagamma, Mercedes Nuñez, Anastasia Lampropoulou","doi":"10.1007/s12325-025-03258-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe the results of a systematic literature review of real-world outcomes with ixekizumab in psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).</p><p><strong>Methods: </strong>Databases, conference proceedings, and additional sources were searched for real-world studies in ≥ 25 patients treated with ixekizumab for PsO, PsA, or axSpA. Data on clinical effectiveness, patient-reported outcomes, treatment patterns, safety, and economic burden were extracted.</p><p><strong>Results: </strong>A total of 118 publications were included, 96 in PsO, 16 in PsA, 5 in both PsO and PsA, and 1 in axSpA. Most focused on clinical effectiveness and treatment patterns. Ixekizumab was effective in real-world settings, and the anti-interleukin (IL)-17A biologics were more effective for skin clearance than comparator biologics. Anti-IL-17A biologics were effective for challenging body areas (nails, scalp, genitals, palmoplantar regions), and ixekizumab was associated with a higher chance of obtaining Dermatology Life Quality Index scores of 0/1 than secukinumab or other biologics. Ixekizumab was associated with generally high persistence/drug survival. No unexpected safety signals were identified.</p><p><strong>Conclusion: </strong>Real-world ixekizumab use for PsO and PsA is effective and safe, with a positive impact on patient quality of life. More data are needed to draw conclusions for real-world ixekizumab use in axSpA.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03258-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To describe the results of a systematic literature review of real-world outcomes with ixekizumab in psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
Methods: Databases, conference proceedings, and additional sources were searched for real-world studies in ≥ 25 patients treated with ixekizumab for PsO, PsA, or axSpA. Data on clinical effectiveness, patient-reported outcomes, treatment patterns, safety, and economic burden were extracted.
Results: A total of 118 publications were included, 96 in PsO, 16 in PsA, 5 in both PsO and PsA, and 1 in axSpA. Most focused on clinical effectiveness and treatment patterns. Ixekizumab was effective in real-world settings, and the anti-interleukin (IL)-17A biologics were more effective for skin clearance than comparator biologics. Anti-IL-17A biologics were effective for challenging body areas (nails, scalp, genitals, palmoplantar regions), and ixekizumab was associated with a higher chance of obtaining Dermatology Life Quality Index scores of 0/1 than secukinumab or other biologics. Ixekizumab was associated with generally high persistence/drug survival. No unexpected safety signals were identified.
Conclusion: Real-world ixekizumab use for PsO and PsA is effective and safe, with a positive impact on patient quality of life. More data are needed to draw conclusions for real-world ixekizumab use in axSpA.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
